Literature DB >> 12126612

The Role of Therapeutic Drug Monitoring in the Management of HIV-infected Patients.

Stephen C. Piscitelli1.   

Abstract

The concept of targeting drug therapy based on plasma concentrations, also called therapeutic drug monitoring (TDM), has been used in the treatment of infectious diseases and other illnesses for decades. A number of clinical trials have demonstrated that drug concentrations are an important factor in response to therapy for HIV, but whether TDM will become a tool for the routine management of HIV infection remains to be determined. The concept of the inhibitory quotient, which integrates drug concentrations and resistance testing, also shows promise in a number of retrospective analyses. Logistical problems still remain with regard to its feasibility, and theoretical issues such as protein binding, variability, and the appropriate time of sampling continue to be debated. A growing body of literature supports the concept of TDM in HIV, but it is important that it be used with other interventions such as resistance testing, adherence monitoring, and patient counseling to be an effective tool in patient management.

Entities:  

Year:  2002        PMID: 12126612     DOI: 10.1007/s11908-002-0028-9

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  14 in total

Review 1.  Therapeutic drug monitoring in HIV infection: current status and future directions.

Authors:  David Back; Giorgio Gatti; Courtney Fletcher; Rodolphe Garaffo; Richard Haubrich; Richard Hoetelmans; Michael Kurowski; Andrew Luber; Concepta Merry; Carlo-Federico Perno
Journal:  AIDS       Date:  2002-03       Impact factor: 4.177

2.  Concentration-targeted therapy and the future of HIV management.

Authors:  Charles W Flexner; Stephen C Piscitelli
Journal:  AIDS       Date:  2002-03       Impact factor: 4.177

3.  High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.

Authors:  A I Veldkamp; G J Weverling; J M Lange; J S Montaner; P Reiss; D A Cooper; S Vella; D Hall; J H Beijnen; R M Hoetelmans
Journal:  AIDS       Date:  2001-06-15       Impact factor: 4.177

4.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

5.  Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Authors:  J P Dieleman; I C Gyssens; M E van der Ende; S de Marie; D M Burger
Journal:  AIDS       Date:  1999-03-11       Impact factor: 4.177

6.  Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.

Authors:  G L Drusano; D Z D'Argenio; S L Preston; C Barone; W Symonds; S LaFon; M Rogers; W Prince; A Bye; J A Bilello
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 7.  Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.

Authors:  E P Acosta; T N Kakuda; R C Brundage; P L Anderson; C V Fletcher
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

8.  Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.

Authors:  Courtney V Fletcher; Peter L Anderson; Thomas N Kakuda; Timothy W Schacker; Keith Henry; Cynthia R Gross; Richard C Brundage
Journal:  AIDS       Date:  2002-03-08       Impact factor: 4.177

9.  Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

Authors:  A Molla; S Vasavanonda; G Kumar; H L Sham; M Johnson; B Grabowski; J F Denissen; W Kohlbrenner; J J Plattner; J M Leonard; D W Norbeck; D J Kempf
Journal:  Virology       Date:  1998-10-25       Impact factor: 3.616

10.  The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Authors:  J M Schapiro; M A Winters; F Stewart; B Efron; J Norris; M J Kozal; T C Merigan
Journal:  Ann Intern Med       Date:  1996-06-15       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.